Skip to content

Evaluate Efficacy, Safety, and Patient Perception of Drizova eye drops with Mild to Moderate Dry Eye Patients

Evaluate Efficacy, Safety, and Patient Perception of Sodium Hyaluronate and Trehalose eye drops with Mild to Moderate Dry Eye Patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094545
Enrollment
100
Registered
2025-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H00-H59- Diseases of the eye and adnexa

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Dr Gautam Parmar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Willing to participate in the study and must sign an ICF indicating that the participant understands the purpose of, and procedures required for the study Male or female Age of above 18 years (completed years) at the time of signing the informed consent. Patients with an OSDI score between 13 and 22. Treatment na?ve patients No history of ocular surgery within the last 6 months. No systemic diseases affecting tear production. History of allergic reactions to any component of the study medication Concurrent use of other ocular medications that could interfere with study outcomes

Exclusion criteria

Exclusion criteria: History of allergic reactions to any component of the study medication Concurrent use of other ocular medications that could interfere with study outcomes

Design outcomes

Primary

MeasureTime frame
Mean change in OSDI score from baselineTimepoint: week 8

Secondary

MeasureTime frame
Mean change in OSA test ( NIBUT, LLT, TMH, and MG loss) from baselineTimepoint: week 4 and 8;Improvemnt in Patient perception scoreTimepoint: week 8;Clinically significant changes in ocular examinationTimepoint: During study period;Incidence and nature of adverse eventsTimepoint: During study period

Countries

India

Contacts

Public ContactGopal Sharma

Sadguru Netra Chikitsalaya

drgsparmar@yahoo.co.in9893328485

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026